KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Return on Assets (2016 - 2025)

CRISPR Therapeutics AG's Return on Assets history spans 10 years, with the latest figure at 0.26% for Q4 2025.

  • For Q4 2025, Return on Assets fell 27.0% year-over-year to 0.26%; the TTM value through Dec 2025 reached 0.26%, down 27.0%, while the annual FY2025 figure was 0.26%, 27.0% down from the prior year.
  • Return on Assets for Q4 2025 was 0.26% at CRISPR Therapeutics AG, down from 0.04% in the prior quarter.
  • Across five years, Return on Assets topped out at 0.18% in Q2 2021 and bottomed at 0.28% in Q4 2022.
  • The 5-year median for Return on Assets is 0.03% (2024), against an average of 0.07%.
  • The largest annual shift saw Return on Assets surged 35bps in 2021 before it crashed -43bps in 2022.
  • A 5-year view of Return on Assets shows it stood at 0.14% in 2021, then crashed by -309bps to 0.28% in 2022, then soared by 104bps to 0.01% in 2023, then skyrocketed by 32bps to 0.02% in 2024, then crashed by -1659bps to 0.26% in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Return on Assets are 0.26% (Q4 2025), 0.04% (Q3 2025), and 0.03% (Q2 2025).